These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25674402)

  • 1. A critical review of brand and generic alendronate for the treatment of osteoporosis.
    Brown JP; Davison KS; Olszynski WP; Beattie KA; Adachi JD
    Springerplus; 2013; 2(1):550. PubMed ID: 25674402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates.
    Olszynski WP; Adachi JD; Davison KS
    J Osteoporos; 2014; 2014():420451. PubMed ID: 25349772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.
    Unnanuntana A; Jarusriwanna A; Songcharoen P
    PLoS One; 2017; 12(7):e0180325. PubMed ID: 28678853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2009 Feb; 25(2):449-52. PubMed ID: 19192989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization.
    Halkin H; Dushenat M; Silverman B; Shalev V; Loebstein R; Lomnicky Y; Friedman N
    Ann Pharmacother; 2007 Jan; 41(1):29-34. PubMed ID: 17190847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide.
    Mori T; Crandall CJ; Ganz DA
    JBMR Plus; 2019 Nov; 3(11):e10233. PubMed ID: 31768491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
    Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy.
    Colombo GL; Montecucco CM
    Clin Cases Miner Bone Metab; 2013 Sep; 10(3):195-8. PubMed ID: 24554931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
    Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
    Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
    Shakweh M; Bravo-Osuna I; Ponchel G
    Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Gastric H
    Phutthatiraphap S; Hayashi Y; Fujii T; Kosugi A; Okada K; Kadozaki T; Ishise T; Sakai H; Onuki Y
    Chem Pharm Bull (Tokyo); 2018; 66(9):896-900. PubMed ID: 30175749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.